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Background: Bilastine, a novel non-sedating second-generation H1-antihistamine, has been widely used
in the treatment of allergic rhinoconjunctivitis and urticaria with a recommended dose of 20 mg once
daily in most European countries since 2010. We evaluated its efﬁcacy and safety in Japanese patients
with chronic spontaneous urticaria (CSU).
Methods: We conducted a multicenter, randomized, double-blind, placebo-controlled phase II/III study
(trial registration No. JapicCTI-142574). Patients (age, 18e74 years) were randomly assigned to receive
bilastine 20 mg, 10 mg or placebo once daily for 2 weeks. The primary efﬁcacy endpoint was the change
from baseline (Day 3 to 0) in total symptom score (TSS) at 2 weeks (Day 8e14), consisting of the itch
and rash scores.
Results: A total of 304 patients were randomly allocated to bilastine 20 mg (101 patients), bilastine 10 mg
(100 patients), and placebo (103 patients). The changes in TSS at 2 weeks were signiﬁcantly decreased by
bilastine 20 mg than did placebo (p < 0.001), demonstrating the superiority of bilastine 20 mg. Bilastine
10 mg also showed a signiﬁcant difference from placebo (p < 0.001). The TSS changes for the bilastine
showed signiﬁcant improvement from Day 1, and were maintained during the treatment period. The
Dermatology Life Quality Index scores were also improved in bilastine than in placebo. The bilastine
treatments were safe and well tolerated.
Conclusions: Two-week treatment with bilastine (20 or 10 mg) once daily was effective and tolerable in
Japanese patients with CSU, demonstrating an early onset of action.
Copyright © 2016, Japanese Society of Allergology. Production and hosting by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Urticaria is one of the most common skin diseases, and the
management of this disease is important because it often causes a
high impairment in the quality of life (QOL).1 Urticaria is charac-
terized by the appearance of itchy wheals and ﬂare that usually
disappear in hours. The lifetime prevalence of chronic spontaneous
urticaria (CSU), deﬁned as episodic or daily hives lasting for 6
weeks, occurs in approximately 1.8% of the adult population with a
period prevalence (past 12 months) of 0.6%e0.8%.2,3y, Institute of Biomedical and
, Minami-ku, Hiroshima 734-
jp (M. Hide).
ety of Allergology.
rgology. Production and hosting by Else
et al., Efﬁcacy and safety of b
lacebo-controlled, parallel-gIn the Japanese guideline for the diagnosis and treatment of
urticaria4 published by the Japanese Dermatological Association in
2011, CSU is deﬁned as the persistence of urticaria for >1 month
without apparent involvement of triggers. This guideline also
described two principles for treating urticaria: (i) removing or
avoiding causative and/or aggravating factors, and (ii) using med-
ications including H1-antihistamines. Concerning medications for
the treatment of urticaria, the guideline states that oral H1-anti-
histamines may be used as a mainstay treatment for virtually all
subtypes of urticaria. However, the efﬁcacy of H1-antihistamines in
treating urticaria is largely variable among subtypes, or individual
patients. Therefore, the aims and nature of the treatment for urti-
caria should be planned, taking into consideration the subtype and
severity of urticaria as well as the speciﬁc conditions of individual
patients. The guideline also recommends second-generation H1-
antihistamines, which have little penetration into the centralvier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
ilastine in Japanese patients with chronic spontaneous urticaria: A
roup phase II/III study, Allergology International (2016), http://
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drug therapy. For symptomatic relief, non-sedating H1-antihista-
mines are also the ﬁrst choice for most subtypes of urticaria in a
recent worldwide guidance/guideline for the management of
CSU.5,6
Bilastine has shown high afﬁnity and selectivity for histamine
H1 receptors, and a potent anti-allergic activity in preclinical
studies.7,8 An overseas clinical study in patients with seasonal
allergic rhinitis demonstrated that a single administration of
bilastine 20 mg showed a rapid onset of action (60 min), and
maintained its efﬁcacy for >24 h.9 Moreover, bilastine requires no
dose adjustment for patients with renal impairment.10 It has been
also reported that a single oral dose of bilastine 20 mg had min-
imal H1 histamine receptor occupancy in the brain (mean
value, 3.92%), and was categorized as a non-sedating antihista-
mine according to the positron emission tomography criteria.11 In
addition, bilastine has been conﬁrmed not to affect driving ac-
tivity at a dose of 20 mg, or even 40 mg, in a driving test.12
Although bilastine at therapeutic and supratherapeutic doses
(20 mg and 100 mg once daily, respectively) had no clinically
signiﬁcant impact on QTc prolongation in electrocardiogram.13
Although bilastine has been authorized and used to treat
allergic rhinitis and urticaria with a recommended dose of 20 mg
once daily in patients aged 12 years or older, in most countries in
Europe since 2010, it has not been approved in Japan.
We conducted a multicenter, randomized, double-blind, pla-
cebo-controlled phase II/III study to evaluate the efﬁcacy, safety,
and dose-response of bilastine at doses of 10 and 20 mg, admin-
istered once a day for 14 days, in Japanese patients with CSU.
Methods
Study design
This study, conducted at 44 centers in Japan, was a multicenter,
randomized, double-blind, placebo-controlled, parallel-group,
phase II/III study in patients with CSU. The primary objectives of
this study were to verify the superiority of bilastine 20 mg over
placebo by using the total symptom score (TSS), and also to
investigate the dose-response of bilastine at doses of 10 and 20 mg.
Eligible patients entered a 4- to 14-day run-in period. A total of
300 patients were planned to be randomized (1:1:1) into one of the
three treatment arms: bilastine 10 mg, bilastine 20 mg, or placebo.
For all active treatments and placebo, the tablets (supplied by Taiho
Pharmaceutical, Tokyo, Japan) had identical appearances to main-
tain the double-blind status. A nondeterministic minimization
methodwas applied to the randomization of patients. The factors in
the dynamic allocation were severity (<25 and 25 points as the
sum of the itch [the sum of daytime and nighttime scores] and the
rash [synthetic] scores for 3 days before randomization), and age
(65 and <65 years). Randomization was done centrally through a
computer (ADJUST, Sapporo, Japan). The day after randomization
was set as the ﬁrst day of drug administration (Day 1). The study
drug was administered once daily in the morning, within 1 h before
or 2 h after breakfast, for 2 weeks. A follow-up visit was scheduled
4e7 days after the end of the treatment. Patients who completed all
of their visits including the follow-up were considered to have
completed the study.
Patients
Male and female patients, 18e74 years old, with a documented
history of CSU, characterized by erythematous skin wheals of
unknown etiology, occurring regularly from 4 weeks or more
before consent acquisition, were recruited. Eligible patients forPlease cite this article in press as: Hide M, et al., Efﬁcacy and safety of
multicenter, randomized, double-blind, placebo-controlled, parallel-g
dx.doi.org/10.1016/j.alit.2016.08.004registration were required to demonstrate a symptom score of at
least 8 (maximum score: 24) as the sum of the itch score (sum of
daytime and nighttime), and at least 5 (maximum score: 9) as the
sum of the rash (synthetic) score during the last 3 days before
registration in the run-in period. Patients were required to record
every symptom scores on the patient diary for the last 3 days
before registration and to record the symptom scores more than
80% in whole the ruin-in period.
Patients were excluded from the study if they had any derma-
tological condition that could interfere with the efﬁcacy evaluation
(including eczema, contact dermatitis, atopic dermatitis,
nummular eczema, autosensitization dermatitis, pompholyx,
asteatotic eczema, lichen simplex chronicus, angioedema, cholin-
ergic urticaria, mechanical urticaria, aspirin-induced urticaria, ur-
ticaria associated with vasculitis or collagen disorder, urticaria with
known causes, urticaria related to thyroid disorders, urticaria pig-
mentosa, food-dependent exercise-induced anaphylaxis, Schnitzler
syndrome, cryopyrin-associated periodic syndrome, psoriasis, or
ichthyosis), a known hypersensitivity to antihistamine, any clini-
cally signiﬁcant condition (cardiovascular, neurological, hepatic,
renal, or malignant diseases), or received ultraviolet light therapy
before entry. Similarly, patients who had received antihistamines
(including H2 receptor antagonists, excluding ebastine), anti-
allergy drugs, nonsteroidal anti-inﬂammatory drugs, neurotropin,
antiplasmin drugs (tranexamic acid), glycyrrhizinate, dia-
minodiphenyl sulfone, psychotropic drugs (antipsychotic drugs,
antidepressants, sleeping pills, or antianxiety drugs), antipruritic
drugs (pregabalin or crotamiton), or drugs for the target diseases
(including Kampo medicines) in the previous 6 days; ebastine in
the previous 7 days; corticosteroids (excluding depot formula-
tions), tacrolimus hydrate, immunological drugs (methotrexate,
cyclophosphamide, mycophenolate mofetil, or omalizumab), or
estrogen in the previous 21 days; corticosteroids (depot formula-
tions), P-glycoprotein inhibitors (ketoconazole, erythromycin,
cyclosporine, or diltiazem), speciﬁc immunotherapy, or nonspeciﬁc
modulation therapy in the previous 30 days; or investigational
drugs in the previous 90 days before randomizationwere excluded.
Efﬁcacy assessments
The primary endpoint was the change from baseline in TSS,
deﬁned as the sum of the rash (synthetic) and itch (mean of day-
time and nighttime) scores, at Week 2 (mean score for Day 8e14
after the ﬁrst drug administration). The baseline values were the
average score during the four consecutive days before the ﬁrst drug
administration (Day -3e0).
We also evaluated the change from baseline in TSS at Day 1e3
(mean score for 3 days) and Week 1 (mean score for Day 1e7 after
the drug administration) as a secondary endpoint. Similar to TSS,
the rash (synthetic, ﬂare, and wheal) score and the itch (daytime
and nighttime) score were evaluated.
The patients assessed their rash score every day by using a four-
point scale (0e3) for the synthetic score, and wheal score
(Supplementary Table 1). The patients assessed their itch score
(daytime and nighttime) every day by using a ﬁve-point scale (0e4)
(Supplementary Table 2). In addition, the patients assessed their
QOL by using the Japanese version of the Dermatology Life Quality
Index (DLQI; ©Dermatology Life Quality Index. A.Y. Finlay, G.K.
Khan, April 1992)14 at the randomization visit (Day 0), at Day 7, and
at the end of treatment (Day 14), or at the early discontinuation
visit in case of withdrawal from the study. The DLQI questionnaire
was a self-administered QOL instrument comprising 10 questions
(each of which is rated on a four-point scale: 0, not at all; 1, a little;
2, a lot; and 3, very much; a not relevant response was also scored
as 0). The DLQI measures the effect of CSU on six domains:bilastine in Japanese patients with chronic spontaneous urticaria: A
roup phase II/III study, Allergology International (2016), http://
M. Hide et al. / Allergology International xxx (2016) 1e9 3symptoms/feelings, daily activities, leisure, work/school, personal
relationships, and treatment inconveniences. The DLQI was sum-
marized by using the overall or individual domains, with summing
of the scores for each question; a higher score indicated greater
impairment in the QOL of the patient. The DLQI has been shown to
be reproducible, valid, and responsive for measuring disease-
related QOL.15 We obtained permission to use DLQI assessment
from Drs. A.Y. Finlay and G.K. Khan (Department of Dermatology,
Cardiff University School of Medicine) before conducting this study.
At each patient visit, the investigator evaluated the overall
improvement according to patient diaries and physical examina-
tion by using a ﬁve-point scale (1, markedly improved; 2, moder-
ately improved; 3, mildly improved; 4, no change; 5, exacerbated;
Supplementary Table 3).16
Safety assessments
Safety was assessed on the basis of the incidence and severity of
adverse events (AEs), laboratory tests (clinical chemistry and he-
matology), and vital signs (blood pressure, body temperature, and
heart rate). AEs were monitored during the treatment and follow-
up periods. The causal relationships for all AEs were categorized
by the investigator as probable, possible, unlikely, or unrelated.
Treatment compliance was assessed through patient diary card
recording.
Statistical analyses
The objective of this study was to verify the superiority of
bilastine 20 mg over placebo as the primary efﬁcacy endpoint for
the full analysis set (FAS) population. A sample size of 270 patients
(90 patients per group) was required to provide a statistical power
of 90% at a two-sided level of signiﬁcance of 5%, assuming a
treatment difference of 0.83 points and a standard deviation of 1.7
points, based on a previous study.17 Assuming that approximately
10% of the patientsmight withdraw from the study, the ﬁnal sample
size was calculated to be 300 patients (100 patients per arm).
Efﬁcacy analyses were performed for the FAS of patients who
were randomized to a treatment, received at least one dose of the
study medication, and completed at least 4 days of diary assess-
ments of TSS (Day 8e14) after receiving the study medication. For
the primary efﬁcacy endpoint, the superiority of bilastine 20 mg
over placebo was analyzed by using an analysis of covariance
(ANCOVA) model including treatment as a factor and baseline as a
covariate. For the secondary analyses of the primary efﬁcacy
endpoint, dose-response was analyzed by using an ANCOVA model
including treatment with contrast coefﬁcients as a factor and
baseline as a covariate. For the secondary efﬁcacy endpoints of the
overall evaluation of response to therapy and the change in DLQI
score, summary statistics were calculated for each treatment group
and compared between groups.
The changes from the baseline in TSS and each symptom score
were analyzed by using an ANCOVA model. We analyzed TSS (the
primary endpoint) by using age and severity (sum of the itch score
during 3 days before registration [sum of daytime and nighttime
scores as the daily score] and the rash [synthetic] score) as strati-
ﬁcation factors.
Safety analyses were performed for the safety population (SP) of
patients who received at least one dose of the study medication.
The incidence of AEs and drug-related AEs was analyzed by using
Fisher's exact tests.
All statistical analyses were performed with SAS software
version 9.2 (SAS Institute, Cary, NC, USA). All reported p values were
two-sided, and p < 0.05 was considered to be statistically
signiﬁcant.Please cite this article in press as: Hide M, et al., Efﬁcacy and safety of b
multicenter, randomized, double-blind, placebo-controlled, parallel-g
dx.doi.org/10.1016/j.alit.2016.08.004Ethical approval and clinical trial registration
This trial was conducted in accordance with the World Medical
Association Declaration of Helsinki and Japanese Good Clinical
Practice guidelines. The protocol was approved by the Institutional
Review Boards of all participating institutions. Informed consent
was obtained from all participants included in the study. This study
was registered with the Japan Pharmaceutical Information Center
(no. JapicCTI-142574).
Results
Study population
Between July 2014 and November 2014, 339 patients were
screened and 304 patients were randomized to one of the three
treatment groups: 101 patients in the bilastine 20 mg, 100 patients
in bilastine 10 mg and 103 patients in placebo (Fig. 1). Thirty-ﬁve
patients were excluded from the study for not meeting the inclu-
sion criteria (n¼ 21), according to the patient's decision (n¼ 8), and
according to the investigator's judgment (n¼ 6). Of the randomized
patients, 294 patients were included in the efﬁcacy analysis (FAS)
and 304 patients were included in the safety analysis (SP). Two
hundred ninety-two patients (>96%) completed the study; 12 pa-
tients were withdrawn from the study (placebo: 9 patients, bilas-
tine 20 mg: 2 patients, bilastine 10 mg: 1 patient). In detail, ﬁve
patients withdrew their consent (placebo: 3 patients, bilastine
20 mg: 1 patient, bilastine 10 mg: 1 patient) and seven patients
were withdrawn owing to a lack of efﬁcacy as judged by the
investigator (placebo: 6 patients, bilastine 20 mg: 1 patient).
The baseline demographic and clinical characteristics for the
FAS population are summarized in Table 1. The number of female
patients was signiﬁcantly higher than that of males in all treatment
groups. Statistically signiﬁcant differences were found in patients'
sex among the three groups (p ¼ 0.009). The baseline demographic
and clinical characteristics were otherwise similar among the
treatment groups, with respect to age, body weight, and efﬁcacy
baseline value (TSS, rash [synthetic] score, itch [mean of daytime
and nighttime] score, and DLQI score). The mean rate of treatment
compliance was similar among the three treatment groups (99.33%
in placebo, 98.97% in bilastine 10 mg, and 98.66% in bilastine
20 mg).
Efﬁcacy
The results of primary efﬁcacy endpoint are shown in Table 2.
The estimated change from baseline in TSS at Week 2 was 3.01
(95% conﬁdence interval [CI]: 3.27 to 2.75) in bilastine 20 mg
and 1.49 (1.75 to 1.22) in placebo. The estimated difference
from placebo was 1.52 (1.89 to 1.15), and there was a signiﬁ-
cant difference between bilastine 20 mg and placebo (p < 0.001),
verifying the superiority of bilastine 20 mg over placebo in the
primary efﬁcacy endpoint. Analysis for the efﬁcacy of bilastine
10 mg was performed according to a predeﬁned statistical protocol.
The estimated change from baseline in TSS at Week 2 was 3.23
(3.48 to 2.98) in bilastine 10 mg, the estimated difference from
placebo was 1.73 (2.09 to 1.37); and the bilastine 10 mg
showed signiﬁcantly decreased TSS at Week 2 compared with
placebo (p < 0.001). On the other hand, the estimated difference
between bilastine 20 mg and 10 mg was 0.22 (0.13 to 0.57); there
was no signiﬁcant difference between them (p¼ 0.225), taking into
account that the efﬁcacy of bilastine 10 mg was comparable to that
of bilastine 20 mg in the primary endpoint (Table 2).
Next, the dose-response of bilastine in the primary efﬁcacy
endpoint was investigated by using the contrast test with contrastilastine in Japanese patients with chronic spontaneous urticaria: A
roup phase II/III study, Allergology International (2016), http://
Patients screened
(n = 339)
Excluded (n = 35)
- Not meeting inclusion criteria (n = 21)
- Patient decision (n = 8)
- Investigator decision (n = 6)
Randomized (n = 304)
Assigned to bilastine 20 mg 
(n = 101)
- Received treatment (n = 101)
A
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n
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t
Assigned to bilastine 10 mg
(n = 100)
- Received treatment (n = 100)
Fo
llo
w
 u
p Discontinued treatment (n = 2) - Patient decision (n = 1)
- Investigator decision (n = 1)
Discontinued intervention (n = 1) 
- Patient decision (n = 1)
A
na
ly
si
s
Safety analysis, SP (n = 101)
Efficacy analysis, FAS (n = 100)
Excluded from efficacy analysis
(n = 1) 
-Missing of efficacy data 
(n = 1)
Safety analysis, SP (n = 100)
Efficacy analysis, FAS (n = 99)
Excluded from efficacy analysis
(n = 1)
- Missing of efficacy data
(n = 1)
Assigned to placebo
(n = 103)
- Received treatment (n = 103)
Discontinued intervention (n = 9) 
- Patient decision (n = 3)
- Investigator decision (n = 6)
Safety analysis,SP (n = 103)
Efficacy analysis, FAS (n = 95)
Excluded from efficacy analysis
(n = 8) 
- Missing of efficacy data
(n = 8)
Fig. 1. Patient disposition. FAS, full analysis set; SP, Safety population.
Table 1
Patient demographics and characteristics at baseline (FAS).
Variable Placebo (n ¼ 95) Bilastine 10 mg (n ¼ 99) Bilastine 20 mg (n ¼ 100) p-Value
Sex [n (%)] Female 69 (72.6%) 83 (83.8%) 65 (65.0%) 0.009
Male 26 (27.4%) 16 (16.2%) 35 (35.0%)
Age (years) [mean ± SD] 39.7 ± 13.3 40.9 ± 12.9 42.0 ± 13.3 0.475
BW (kg/m2) [mean ± SD] 58.0 ± 11.27 57.99 ± 11.69 60.55 ± 12.32 0.213
Baseline value [mean ± SD]
TSS 4.49 ± 0.95 4.54 ± 0.91 4.54 ± 0.89 0.915
Itching (daytime and
nighttime) score
2.44 ± 0.60 2.47 ± 0.62 2.47 ± 0.59 0.916
Rash (synthetic) score 2.05 ± 0.45 2.07 ± 0.42 2.07 ± 0.42 0.953
QOL score (total DLQI score) 7.5 ± 4.5 8.3 ± 5.0 8.0 ± 4.6 0.518
Analyzed with Fisher's exact test.
FAS, full analysis set; BW, body weight; DLQI, Dermatology Life Quality Index; QOL, quality of life; TSS, total symptom score.
M. Hide et al. / Allergology International xxx (2016) 1e94coefﬁcients of (1, 0,1), (2,1,1), and (1, 1,2) for the treatment
groups (placebo, bilastine 10 mg, and bilastine 20 mg, respec-
tively). No clear dose-relationship was observed by the contrast
test (p < 0.001 in each contrast coefﬁcients), however, each F-
value in the contrast test was 69.884, 105.980, and 17.342 for the
contrast coefﬁcients (1, 0, 1), (2, 1, 1), and (1, 1, 2), respec-
tively. The F-value by using (2, 1, 1) was greatest than with the
others. The same results were obtained from the contrast test in
the secondary endpoints (change in synthetic rash score and itch
score at Week 2) (data not shown). These results suggested that
the dose-response of bilastine might be close to the 10 mg dose
saturation.
The results of the secondary efﬁcacy endpoints are summarized
in Table 3. The changes from baseline in TSS were greater in the
bilastine groups than in the placebo across Day 1e3, Week 1, and
Week 2 (p < 0.001 for bilastine 20 or 10 mg vs. placebo). ThePlease cite this article in press as: Hide M, et al., Efﬁcacy and safety of
multicenter, randomized, double-blind, placebo-controlled, parallel-g
dx.doi.org/10.1016/j.alit.2016.08.004changes in rash (synthetic, ﬂare, and wheal) scores and itch (day-
time, nighttime, and mean of daytime and nighttime) scores were
also greater in the bilastine groups than in the placebo from the
early period of Day 1e3 through Week 2.
Figure 2 shows the changes from baseline in daily TSS (A), itch
(B) and synthetic rash score (C). The daily TSS, itch, and rash score
in placebo gradually decreased in a treatment day-dependent
manner. The values for both bilastine 20 mg and 10 mg treat-
ments dramatically decreased from Day 1 (ﬁrst drug administra-
tion), and were maintained through Day 14. The changes from
baseline in daily TSS, itch score, and rash score for the bilastine
treatments showed signiﬁcant differences during the treatment
period in comparisonwith placebo (Student's t-test: p < 0.001, from
Day 1e14).
It is well known that CSU has a signiﬁcant impact on QOL.
Therefore, we investigated the effect of bilastine on QOL in patientsbilastine in Japanese patients with chronic spontaneous urticaria: A
roup phase II/III study, Allergology International (2016), http://
Table 3
Secondary efﬁcacy endpoints: mean change from baseline in TSS, rash score, and itch score by treatment period (FAS).
Placebo (n ¼ 95) Bilastine 10 mg (n ¼ 99) Bilastine 20 mg (n ¼ 100)
TSS Baseline Mean ± SD 4.49 ± 0.95 4.54 ± 0.91 4.54 ± 0.89
Day 1e3 Estimated change (95% CI) 0.88 (1.14 to 0.62) 2.93 (3.19 to 2.68)* 2.62 (2.87 to 2.37)*
Week 1 1.07 (1.32 to 0.82) 2.98 (3.22 to 2.74)* 2.74 (2.98 to 2.50)*
Week 2 1.50 (1.75 to 1.24) 3.23 (3.48 to 2.98)* 3.01 (3.26 to 2.76)*
Rash (synthetic) score Baseline Mean ± SD 2.05 ± 0.45 2.07 ± 0.42 2.07 ± 0.42
Day 1e3 Estimated change (95% CI) 0.44 (0.57 to 0.31) 1.31 (1.44 to 1.18)* 1.19 (1.32 to 1.06)*
Week 1 0.54 (0.67 to 0.42) 1.33 (1.45 to 1.20)* 1.24 (1.36 to 1.12)*
Week 2 0.72 (0.85 to 0.60) 1.44 (1.57 to 1.32)* 1.38 (1.50 to 1.25)*
Rash (ﬂare) score Baseline Mean ± SD 2.09 ± 0.50 2.08 ± 0.47 2.09 ± 0.50
Day 1e3 Estimated change (95% CI) 0.39 (0.53 to 0.26) 1.21 (1.34 to 1.08)* 1.12 (1.26 to 0.99)*
Week 1 0.47 (0.60 to 0.34) 1.23 (1.36 to 1.10)* 1.17 (1.30 to 1.04)*
Week 2 0.65 (0.79 to 0.52) 1.38 (1.51 to 1.25)* 1.32 (1.45 to 1.19)*
Rash (wheal) score Baseline Mean ± SD 2.01 ± 0.62 1.92 ± 0.63 1.95 ± 0.66
Day 1e3 Estimated change (95% CI) 0.40 (0.54 to 0.26) 1.31 (1.44 to 1.17)* 1.22 (1.36 to 1.09)*
Week 1 0.49 (0.62 to 0.36) 1.35 (1.48 to 1.23)* 1.29 (1.42 to 1.17)*
Week 2 0.67 (0.80 to 0.54) 1.46 (1.58 to 1.33)* 1.41 (1.54 to 1.28)*
Itch (mean of daytime
and nighttime) score
Baseline Mean ± SD 2.44 ± 0.60 2.47 ± 0.62 2.47 ± 0.59
Day 1e3 Estimated change (95% CI) 0.44 (0.58 to 0.29) 1.62 (1.77 to 1.48)* 1.43 (1.57 to 1.29)*
Week 1 0.53 (0.67 to 0.39) 1.66 (1.79 to 1.52)* 1.50 (1.63 to 1.36)*
Week 2 0.78 (0.92 to 0.63) 1.79 (1.93 to 1.65)* 1.63 (1.77 to 1.50)*
Itch (daytime) score Baseline Mean ± SD 2.73 ± 0.66 2.78 ± 0.58 2.74 ± 0.64
Day 1e3 Estimated change (95% CI) 0.38 (0.54 to 0.21) 1.74 (1.90 to 1.58)* 1.53 (1.69 to 1.37)*
Week 1 0.49 (0.64 to 0.33) 1.81 (1.96 to 1.65)* 1.62 (1.77 to 1.47)*
Week 2 0.81 (0.97 to 0.64) 1.95 (2.11 to 1.79)* 1.81 (1.97 to 1.65)*
Itch (nighttime) score Baseline Mean ± SD 2.15 ± 0.71 2.17 ± 0.83 2.21 ± 0.74
Day 1e3 Estimated change (95% CI) 0.50 (0.65 to 0.35) 1.51 (1.66 to 1.36)* 1.33 (1.47 to 1.18)*
Week 1 0.57 (0.71 to 0.42) 1.51 (1.65 to 1.37)* 1.38 (1.51 to 1.24)*
Week 2 0.74 (0.88 to 0.60) 1.63 (1.77 to 1.49)* 1.46 (1.60 to 1.33)*
Analysis of covariance model including treatment as factor and baseline as a covariate.
*p < 0.001 for Bilastine 10 mg/20 mg vs. placebo.
Baseline: mean scores of Day 3 to 0.
Day 1e3: mean score for Day 1e3.
Week 1: mean score for Day 1e7.
Week 2: Mean score for Day 8e14.
FAS, full analysis set; CI, conﬁdence interval.
Note: There was no signiﬁcant difference between bilastine 10 mg and 20 mg.
Table 2
Mean change from baseline in TSS at Week 2 (FAS).
(A) Primary analysis
Bilastine 20 mg (n ¼ 100) Placebo (n ¼ 95)
Baseline Mean ± SD 4.54 ± 0.89 4.49 ± 0.95
Week 2 Mean ± SD 3.02 ± 1.63 1.47 ± 1.24
Estimated change (95% CI) 3.01 (3.27 to 2.75) 1.49 (1.75 to 1.22)
Estimated difference (95% CI)y 1.52 (1.89 to 1.15) e
p-Value vs. placebo <0.001 e
(B) Secondary analysis
Bilastine 20 mg (n ¼ 100) Bilastine 10 mg (n ¼ 99) Placebo (n ¼ 95)
Baseline Mean ± SD 4.54 ± 0.89 4.54 ± 0.91 4.49 ± 0.95
Week 2 Mean ± SD 3.02 ± 1.63 3.24 ± 1.45 1.47 ± 1.24
Estimated change (95% CI) 3.01 (3.26 to 2.76) 3.23 (3.48 to 2.98) 1.50 (1.75 to 1.24)
Estimated difference (95% CI)y 1.51 (1.87 to 1.16) 1.73 (2.09 to 1.37) e
p-Value vs. placebo <0.001 <0.001 e
Estimated difference (95% CI)z 0.22 (0.13 to 0.57) e e
p-Value vs. bilastine 10 mg 0.225 e e
Analysis of covariance model including treatment as factor and baseline as a covariate.
Baseline: mean score of Day 3 to 0.
Week 2: mean score of Day 8e14.
TSS, total symptom score; FAS, full analysis set; CI, conﬁdence interval.
y Estimated difference from placebo.
z Estimated difference from bilastine 10 mg.
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individual domains score) are shown in Figure 3. The change from
baseline in the total DLQI score at Day 14 was greater in the
bilastine groups than in placebo (6.4 ± 5.0, 7.2 ± 5.2,Please cite this article in press as: Hide M, et al., Efﬁcacy and safety of b
multicenter, randomized, double-blind, placebo-controlled, parallel-g
dx.doi.org/10.1016/j.alit.2016.08.004and 4.0 ± 3.9 in the bilastine 20 mg, 10 mg and placebo, respec-
tively; p < 0.001 vs. placebo for both bilastine groups). Signiﬁcant
improvement of the total DLQI score by the bilastine treatments
was also observed at Day 7 and the ﬁnal assessment (data notilastine in Japanese patients with chronic spontaneous urticaria: A
roup phase II/III study, Allergology International (2016), http://
Fig. 2. Change from baseline in the daily total symptom score (A), daily itch score (B) or daily synthetic rash score (C) (FAS). Each datum represents the mean and SE. *p < 0.001; vs.
placebo in Student's t-test. FAS, full analysis set; TSS, total symptom score.
Fig. 3. Change from baseline in the DLQI score (FAS). DLQI scores indicate the sum of all scores (total DLQI) or categorization by the individual six domains including symptoms/
feeling, daily activities, leisure, work/school, and personal relationship. Each datum represents the mean and SE. *p < 0.05, **p < 0.01, ***p < 0.001, vs. placebo in Student's t-test. FAS,
full analysis set; DLQI, Dermatology Life Quality Index.
M. Hide et al. / Allergology International xxx (2016) 1e96
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multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II/III study, Allergology International (2016), http://
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Fig. 4. Overall improvement as assessed by the investigators on Day 14 (FAS).
*p < 0.01; vs. placebo in Fisher's exact test. FAS, full analysis set.
Table 4
Adverse events reported during 2 weeks of treatment (SP).
Placebo
(n ¼ 103)
n (%)
Bilastine 10 mg
(n ¼ 100)
n (%)
Bilastine 20 mg
(n ¼ 101)
n (%)
Patients reporting 1 AE 20 (19.4%) 24 (24.0%) 14 (13.9%)
Incidence of AEy 2% in
any treatment group
4 (3.9%) 5 (5.0%) 4 (4.0%)
Withdrawals due to AEs 0 0 0
Serious AEs 0 0 0
Nervous system
disordersz
Dizzinessy 0 (0.0%) 1 (1.0%) 0 (0.0%)
Headachey 1 (1.0%) 3 (3.0%) 2 (2.0%)
Hypesthesiay 0 (0.0%) 1 (1.0%) 0 (0.0%)
Somnolencey 3 (2.9%) 2 (2.0%) 0 (0.0%)
Drug-related AEs 3 (2.9%) 6 (6.0%) 2 (2.0%)
Gastrointestinal disordersz 1 (1.0%) 3 (3.0%) 0 (0.0%)
General disorders
and administration
site conditionsz
2 (1.9%) 2 (2.0%) 0 (0.0%)
Investigationsz 0 (0.0%) 0 (0.0%) 1 (1.0%)
Nervous system disordersz 1 (1.0%) 2 (2.0%) 1 (1.0%)
Headachey 0 (0.0%) 0 (0.0%) 1 (1.0%)
Somnolencey 1 (1.0%) 2 (2.0%) 0 (0.0%)
SP, safety population; AEs, adverse events.
y MedDRA (ver. 17.1) preferred term.
z MedDRA (ver. 17.1) system organ class.
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investigated, the symptoms/feeling, daily activities, and leisure
were signiﬁcantly improved by bilastine 20 mg and 10 mg than by
placebo.
Figure 4 shows the overall improvement on Day 14. The per-
centages of patients evaluated as improved (markedly improved
plus moderately improved) by the investigator at Day 7, Day 14, and
the ﬁnal assessment were 71.0% (71/100), 74.7% (74/99), and 74.7%
(74/99) in bilastine 20 mg; 78.8% (78/99), 84.7% (83/98), and 84.8%
(84/99) in bilastine 10 mg; and 16.8% (16/95), 30.9% (29/94), and
31.6% (30/95) in placebo, respectively. There were signiﬁcant dif-
ferences between bilastine and placebo at all assessment time
points (Fisher's exact test: p < 0.001).Analysis of subgroups in the FAS
There were no signiﬁcant differences in the change from base-
line in TSS at Day 1e3, Week 1, and Week 2, or in the intergroup
comparisons between the severity of CSU (<25 or25 points as the
sum of the itch [the sum of daytime and nighttime scores] and the
rash [synthetic] score for 3 days before randomization), age (65 or
<65 years), and sex (male or female) (data not shown).Safety
Safety analyses were conducted in the SP, comprising 304 pa-
tients. The AEs reported during 2 weeks of treatment are summa-
rized in Table 4. AEs reported during the study were of mild or
moderate intensity, and of similar type and incidence across the
three treatment groups. The proportions of patients with at least
one AE and drug-related AEwere similar across the groups (Fisher's
exact test, AE; placebo vs. bilastine 20 mg: p ¼ 0.349; placebo vs.
bilastine 10 mg: p ¼ 0.497; drug-related AE; placebo vs. bilastine
20 mg: p ¼ 1.000; placebo vs. bilastine 10 mg: p ¼ 0.327).
The most frequently reported AE in this study was nasophar-
yngitis. The incidence of AEs classiﬁed as nervous system disorders,
which are class effects of H1-antihistamines, was reported as fol-
lows: somnolence in 2.0% (2/100) in the bilastine 10 mg, and 2.9%
(3/103) in placebo; headache in 2.0% (2/101) in bilastine 20 mg,
3.0% (3/100) in bilastine 10 mg, and 1.0% (1/103) in placebo; and
dizziness and hypesthesia in 1.0% (1/100, each) in bilastine 10 mg.
There were no serious AEs and no deaths. No patients withdrew as
a result of AEs. Drug-related AEs were reported by two patientsPlease cite this article in press as: Hide M, et al., Efﬁcacy and safety of b
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dx.doi.org/10.1016/j.alit.2016.08.004(2.0%) in bilastine 20 mg, six patients (6.0%) in bilastine 10 mg, and
three patients (2.9%) in placebo. The drug-related AEs reported
were increased total bilirubin and headaches in bilastine 20 mg;
somnolence, abdominal discomfort, constipation, nausea, fatigue,
and dry mouth in bilastine 10 mg; and stomatitis, tooth pain, chest
pain, dry mouth, and somnolence in placebo. There were no clini-
cally signiﬁcant changes from baseline values in any laboratory test,
body temperature, heart rate, or systolic or diastolic blood pressure
in any treatment group.
Discussion
This was the ﬁrst randomized, double-blind, placebo-controlled,
phase II/III study to evaluate the efﬁcacy, safety, and dose-response
of bilastine in Japanese patients with CSU. The patients took
bilastine 20mg,10 mg, or matching placebo tablet once a day for 14
days.
Bilastine at a dose of 20 mg exhibited superiority over placebo
with respect to the primary efﬁcacy endpoint (the change from
baseline in TSS at Week 2). Similar to bilastine 20 mg, bilastine
10 mg signiﬁcantly decreased TSS than did placebo. There was no
signiﬁcant difference between the bilastine treatments. Similar
results were obtained in the secondary efﬁcacy endpoints.
Accordingly, the dose-response of bilastine might be close to the
10mg dose saturation in the present study. Our results on the dose-
response of bilastine were similar to the previous results of the
phase II study of bilastine in patients with CSU reported by Audi-
cana et al.18 These authors assessed the efﬁcacy, safety, and dose-
response of bilastine at doses of 10, 20, and 30 mg once daily for
4 weeks. As the result, all bilastine treatments showed a signiﬁcant
difference in the change from baseline in TSS (sum of pruritus
severity, number of wheals, and maximum size of wheal scores) at
4 weeks in comparison with placebo, indicating that the dose-
response of bilastine was not clear within the dose range of
10e30 mg. As it is well known that the efﬁcacy of H1-antihista-
mines on urticaria is largely variable among subtypes or individual
patients,4 further study may be necessary for patients with CSU
refractory to recommended doses of antihistamines as done usingilastine in Japanese patients with chronic spontaneous urticaria: A
roup phase II/III study, Allergology International (2016), http://
M. Hide et al. / Allergology International xxx (2016) 1e98other antihistamines, such as desloratadine and levocetirizine.19
The results of the present study suggest that bilastine 10 mg is an
effective dose for the treatment of general Japanese patients with
CSU.
All symptom scores (TSS, rash [ﬂare, wheal, and synthetic]
scores, and itch [daytime, nighttime, and mean of daytime and
nighttime] scores) were signiﬁcantly improved from the early stage
(Day 1e3) in the bilastine groups in comparison with placebo. In
particular, the daily TSS, itch score, and synthetic rash score showed
a signiﬁcant decrease fromDay 1 in the bilastine treatments (Fig. 2),
indicating an early onset of action of bilastine for the treatment of
CSU. The appropriateness of the dosage regimen of bilastine with a
dosing of once a day could be conﬁrmed with the comparison of
daytime and nighttime itch scores in this study: (i) all patients took
the study drug once a day in the morning; (ii) both bilastine 20 mg
and 10 mg treatments signiﬁcantly improved the daytime and
nighttime itch scores at all assessment time points than did pla-
cebo; (iii) although the decreases in the estimated change in the
daytime itch scores for the bilastine treatments were greater than
those for the nighttime scores, the 95% CIs of the estimated dif-
ference from placebo in the bilastine treatments overlapped at all
assessment time points (Table 3). Therefore, it could be concluded
that the efﬁcacy of once daily administration of bilastine continues
throughout the day.
Additionally, we examined QOL by using the validated DLQI.15 As
a result, both bilastine treatments signiﬁcantly improved the total
DLQI score, as well as the individual domain scores, including
symptoms/feeling, daily activities, and leisure (Fig. 3). To facilitate
the clinical interpretation of the DLQI scores, a banding system has
been suggested as follows: DLQI scores: 0e1 ¼ no effect,
2e5¼ small effect, 6e10¼moderate effect,11e20¼ very large, and
21e30 ¼ extremely large effect.20 The mean and SD of the total
DLQI score at baseline was 8.0 ± 4.6 in bilastine 20 mg, 8.3 ± 5.0 in
bilastine 10 mg, and 7.5 ± 4.5 in placebo. After 2 weeks of treat-
ment, the total DLQI score was decreased to 1.6 ± 2.7 in bilastine
20 mg, 1.0 ± 1.7 in bilastine 10 mg, and 3.6 ± 2.9 in placebo. When
the patients' QOL in treatments were classiﬁed by the mean of the
total DLQI score according to this criteria, bilastine treatments
changed to “no effect” on Day 14 from “moderate effect” at baseline
(two-rank reduction). However, placebo treatment changed to
“small effect” on Day 14 from “moderate effect” at baseline (one-
rank reduction). In addition, Shikiar et al.21 reported that the
minimal important difference threshold for the DLQI in the range of
2.24e3.10 is recommended in interpreting the results for patients
with CSU. The estimated difference from placebo in the total DLQI
score was 2.5 (3.7 to 1.2) in bilastine 20 mg and 3.2 (4.5
to 1.9) in bilastine 10 mg; the differences in the bilastine treat-
ments were ﬁt in the beneﬁcial threshold in the present Japanese
study. These results suggested that bilastine at 20 or 10mgwas also
effective in improving QOL in patients with CSU irrespectively of
ethnicity.
The overall improvement has been used to investigate the efﬁ-
cacy of H1-antihistamines in Japanese clinical studies for CSU.
Accordingly, we used the overall improvement as judged by the
investigators in the present study. As a result, bilastine treatments
signiﬁcantly increased the ratio of improved patients (markedly
improved plus moderately improved) than did placebo (Fig. 4). In
other H1-antihistamines in double-blind, placebo-controlled
comparative trials in Japanese patients with CSU, the percentages of
patients evaluated by the investigator as improved at the ﬁnal
assessment were 80.5% (loratadine, 10 mg, once a day),16 77.7%
(olopatadine hydrochloride, 5 mg, twice a day),22 and 69.1%
(bepotastine besilate, 10 mg, twice a day).23 The overall improve-
ment of bilastine treatments, 74.7% (20 mg) and 84.8% (10 mg),
indicates that the clinical efﬁcacy of bilastine for the overallPlease cite this article in press as: Hide M, et al., Efﬁcacy and safety of
multicenter, randomized, double-blind, placebo-controlled, parallel-g
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Furthermore, Zuberbier et al.17 reported that bilastine 20 mg once
daily signiﬁcantly improved the TSS change from baseline at 4
weeks than did placebo, and it was comparable to levocetirizine
hydrochloride 5 mg in a randomized, double-blind, placebo-
controlled comparative phase III study in patients with chronic
idiopathic urticaria (CSU).
Concerning the safety of the bilastine treatments, no serious AEs
were reported in this study. There was no difference in the inci-
dence of AEs between bilastine and placebo, and between different
doses of bilastine in the treatments. A small population of the pa-
tients in bilastine groups developed nervous system disorders, the
class effect AEs of H1-antihistamines. However, the incidences were
comparable to those in the placebo group. No other noteworthy
drug-related AEs was observed, as compared with those reported
overseas.24 Thus, bilastine 20 and 10 mg showed a favorable safety
proﬁle in Japanese patients with CSU.
Meanwhile, the present study was conducted within a limited
administration period of 2 weeks; the period of drug therapy for
CSU is longer in actual clinical settings.4 Therefore, future studies
are needed to examine the safety and efﬁcacy of long-term
administration of bilastine to patients with CSU. During the same
period of this study, a long-term administration study of bilastine in
Japanese patients with CSU or pruritus accompanied by skin dis-
eases was conducted, and the results of this study are awaited.
Differences between bilastine groups and placebo group in the
daily TSS, itch score, rash score (Fig. 2) or DLQI scores (Fig. 3) among
secondary efﬁcacy endpoints were analyzed by the t-test according
to the protocol approved the ethics committee. The same signiﬁ-
cance of differences was proved by the Bonferroni's multiple
comparison tests as well.
In conclusion, 2-week treatment with bilastine at doses of 20
and 10 mg once a day was effective and tolerable in Japanese pa-
tients with CSU. Moreover, the efﬁcacy of bilastine exhibited early
onset of action, as evidenced by the relief of CSU symptoms by
bilastine treatment at 1 day after the administration. These results
conﬁrm that bilastine is a safe and effective treatment for the
management of Japanese patients with CSU.
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